|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3940414243444546474849...6768» |
- | Trial completion: Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P0, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller: MS-275 in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=75, Completed, Sponsor: Herbert Irving Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Metastases: PS-341 in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Mayo Clinic
No longer recruiting --> Completed Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=200, Completed, Sponsor: West of Scotland Lymphoma Group
Active, not recruiting --> Completed Recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Northwestern University
Recruiting --> Completed Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion, Pre-transplantation: Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion: SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=21, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Tipifarnib in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Suspended --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Completed Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Post-transplantation: Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | melphalan / Generic mfg.
Trial completion: Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Northwestern University
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | LymphoCide Y-90 (epratuzumab Y-90) / Gilead, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=18, Completed, Sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion, HEOR: Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy (clinicaltrials.gov) - Feb 19, 2014
P3, N=275, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | topotecan / Generic mfg., 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=30, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | vincristine / Generic mfg.
Trial completion: Bryostatin and Vincristine in B-Cell Malignancies (clinicaltrials.gov) - Feb 19, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation (clinicaltrials.gov) - Feb 19, 2014
P2, N=22, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Interleukin-12 in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion: High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=66, Completed, Sponsor: Case Comprehensive Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=27, Completed, Sponsor: University of Arizona
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | decitabine / Generic mfg.
Trial completion, Metastases: Decitabine in Treating Patients With Melanoma or Other Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: California Cancer Consortium
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion, Combination therapy: SWOG-S1A95: Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | melphalan / Generic mfg.
Trial completion: High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse (clinicaltrials.gov) - Feb 19, 2014
P2, N=50, Completed, Sponsor: Mayo Clinic
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial completion: Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=312, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Metastases: Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Hoag Memorial Hospital Presbyterian
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial termination: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=30, Terminated, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Completed --> Terminated; TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved
- ||||| Promacta (eltrombopag) / Novartis
Enrollment change: PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) - Feb 19, 2014
P3, N=92, Completed, Sponsor: GlaxoSmithKline
Completed --> Terminated; TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved N=75 --> 92
- ||||||| Promacta (eltrombopag) / Novartis
Trial completion: PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) - Feb 19, 2014
P3, N=92, Completed, Sponsor: GlaxoSmithKline
N=75 --> 92 Active, not recruiting --> Completed
- Trial completion: Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=292, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Recruiting --> Completed
- || AZD1480 / AstraZeneca
Enrollment change, Tumor mutational burden: Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (clinicaltrials.gov) - Feb 17, 2014
P1, N=65, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed N=35 --> 65
- Onureg (azacitidine oral) / BMS
Trial suspension: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Feb 13, 2014
P1, N=18, Suspended, Sponsor: Celgene Corporation
N=35 --> 65 Not yet recruiting --> Suspended
- | Empliciti (elotuzumab) / AbbVie, BMS
Biomarker, Enrollment closed, Monotherapy: Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (clinicaltrials.gov) - Feb 13, 2014
P2, N=40, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Suspended Recruiting --> Active, not recruiting
- Empliciti (elotuzumab) / AbbVie, BMS
Enrollment closed, Combination therapy: Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function (clinicaltrials.gov) - Feb 13, 2014
P1, N=26, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (clinicaltrials.gov) - Feb 13, 2014
P1, N=57, Completed, Sponsor: National Cancer Institute (NCI)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| I.V.-Globulin SN (human immune globulin intravenous) / Green Cross
New P3 trial: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia (clinicaltrials.gov) - Feb 12, 2014
P3, N=70, Not yet recruiting, Sponsor: Green Cross Corporation
- NovoSeven (eptacog alfa) / Novo Nordisk
Observational data, Enrollment change: Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency (clinicaltrials.gov) - Feb 11, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: Novo Nordisk
Active, not recruiting --> Completed N=15 --> 36
- ||||| Idelvion (albutrepenonacog alfa) / CSL Behring
Enrollment closed: A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B (clinicaltrials.gov) - Feb 10, 2014
P2/3, N=60, Active, not recruiting, Sponsor: CSL Behring
N=15 --> 36 Recruiting --> Active, not recruiting
- ||| balixafortide (POL 6326) / Spexis
Enrollment change, Metastases: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 1, 2014
P1/2, N=60, Recruiting, Sponsor: Polyphor Ltd.
Recruiting --> Active, not recruiting N=90 --> 60
- Trial completion: Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 31, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
N=90 --> 60 Active, not recruiting --> Completed
- ||||| blisibimod (A-623) / Anthera Pharma
Trial initiation date: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - Jan 30, 2014
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Dec 2014
- Enrollment change: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2014
P2, N=10, Completed, Sponsor: Washington University School of Medicine
Initiation date: Dec 2013 --> Dec 2014 N=40 --> 10
- Trial completion: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2014
P2, N=10, Completed, Sponsor: Washington University School of Medicine
N=40 --> 10 Active, not recruiting --> Completed